A Phase 3 interventional study of Esomeprazole 40 mg and Esomeprazole 20 mg in Gastric Ulcer and Duodenal Ulcer, sponsored by AstraZeneca. Completed at 191 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.
Among the 11 studies testing esomeprazole in Stomach Ulcer, this one has the largest enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 3rd registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,426 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Stomach Ulcer by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 3, and was the 3rd registered.
AstraZeneca’s Stomach Ulcer studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing esomeprazole in Stomach Ulcer, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 17 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Esomeprazole 40 mg
Drug: Esomeprazole 40 mg
Esomeprazole 20 mg
Drug: Esomeprazole 20 mg
Placebo
Drug: Placebo
Esomeprazole 40 mg once daily
Esomeprazole 20 mg once daily
Placebo once daily
Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).
The occurrence of ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
Time frame: During 26 weeks
Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.
The occurrence of gastric ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
Time frame: During 26 weeks
Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.
The occurrence of duodenal ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
Time frame: During 26 weeks
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence.
Time frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence.
Time frame: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
Number of Participants With Gastric and/or Duodenal Erosions.
Time frame: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
The first subject was randomized 22 February 2007 and last subject completed 28 August 2008. Cardiologists, primary care physicians and gastroenterologists were the primary target investigators.
| Milestone | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Started | 817 | 804 | 805 |
| Completed | 711 | 686 | 637 |
| Not completed | 106 | 118 | 168 |
| Withdrew: Protocol violation | 19 | 28 | 32 |
| Withdrew: Adverse event | 26 | 33 | 28 |
| Withdrew: Lack of efficacy | 7 | 8 | 48 |
| Withdrew: Withdrawal by subject | 40 | 34 | 47 |
| Withdrew: Lost to follow-up | 5 | 6 | 5 |
| Withdrew: Safety reasons | 3 | 1 | 3 |
| Withdrew: Various reason specified | 6 | 8 | 5 |
The occurrence of ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| percentage of participants | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s). | 1.35 | 1 | 6.58 |
The occurrence of gastric ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| percentage of participants | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced the Occurence of Gastric Ulcer. | 1.1 | 0.75 | 4.1 |
The occurrence of duodenal ulcer (mucosal break measuring \>= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| percentage of participants | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer. | 0.24 | 0.25 | 2.73 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence.
| participants | Esomeprazole 40 mg | Esomeprazole 20 mg | Placbo |
|---|---|---|---|
| Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit. | 591 | 577 | 504 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence.
| participants | Esomeprazole 40 mg | Esomeproazole 20 mg | Placebo |
|---|---|---|---|
| Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit. | 554 | 537 | 451 |
| participants | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Number of Participants With Gastric and/or Duodenal Erosions. | 214 | 213 | 380 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 40 | — | — | — |
| Esomeproazole 20 | — | — | — |
| Placebo | — | — | — |
| Event | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| Cardiac ArrestCardiac disorders | 0/814 | 2/799 | 1/801 |
| Cerebrovascular AccidentNervous system disorders | 1/814 | 2/799 | 0/801 |
| Transient Ischaemic AttackNervous system disorders | 0/814 | 2/799 | 0/801 |
| Angina PectorisCardiac disorders | 2/814 | 0/799 | 1/801 |
| Angina UnstableCardiac disorders | 2/814 | 0/799 | 0/801 |
| Coronary Artery DiseaseCardiac disorders | 2/814 | 1/799 | 1/801 |
| Inguinal HerniaGastrointestinal disorders | 2/814 | 0/799 | 1/801 |
| Pancreatitis AcuteGastrointestinal disorders | 2/814 | 1/799 | 0/801 |
| Acute Coronary SyndromeCardiac disorders | 0/814 | 1/799 | 0/801 |
| Atrial FibrillationCardiac disorders | 0/814 | 1/799 | 1/801 |
| Event | Esomeprazole 40 | Esomeproazole 20 | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/814 | 26/799 | 18/801 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 11/814 | 16/799 | 13/801 |
| Age, Categorical(Participants) | Esomeprazole 40 | Esomeproazole 20 | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 240 | 246 | 260 | 746 |
| >=65 years | 577 | 558 | 545 | 1680 |
| Sex: Female, Male(Participants) | Esomeprazole 40 | Esomeproazole 20 | Placebo | Total |
|---|---|---|---|---|
| Female | 380 | 375 | 402 | 1157 |
| Male | 437 | 429 | 403 | 1269 |
Showing the first 100 of 191 sites across 20 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole